Glaxosmithkline Pharmaceuticals Limited

BSE: 500660 NSE: GLAXO
Glaxosmithkline Pharmaceuticals Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24239MH1924PLC001151 Incorporated 13 November 1924 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: GLAXO · BSE: 500660 Public Limited Company pharma Fortune MNC 500 · #183 Nifty 500
Data last updated
Market Cap
₹42,318 Cr
GLAXO · NSE
Share Price
₹2,515.10
+0.68% today
Revenue
₹3,822 Cr
FY 2025-26 · +1.9% YoY
EBITDA
₹1,309 Cr
Margin 34.3%
Net Profit
₹962 Cr
FY 2025-26 · +10.1% YoY
P/E (TTM)
39.4x
P/B 18.3x
ROE
49.1%
ROCE 59.0%
Debt / Equity
0.01
Interest cover 0.2x

About Glaxosmithkline Pharmaceuticals Limited

Data last updated:

Glaxosmithkline Pharmaceuticals Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 13 November 1924 and has been in existence for over 102 years.

Glaxosmithkline Pharmaceuticals is ranked #183 on the Fortune MNC 500 India (2026). It is part of the Nifty 500 and BSE 500 indices.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24239MH1924PLC001151. Its GSTIN is 27AAACG4414B1Z8 (Maharashtra). The company holds 28 GST registrations, of which 24 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 500660 and NSE: GLAXO.

The company has an authorised share capital of ₹180 Cr and a paid-up capital of ₹169.41 Cr. It was formerly known as British Drug Houses (India) Private Limited and British Drug Houses (India) Limited. It is led by directors including Bhushan Arun Akshikar (Managing Director) and Ronojit Biswas (Whole-Time Director).

Its last annual general meeting (AGM) was held on 27 June 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Gsk House Dr Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹3,821.67 Cr, a growth of 1.9% compared to the previous year. For the same year it recorded a net profit of ₹962.15 Cr (net margin 25.2%) and EBITDA of ₹1,309.2 Cr (EBITDA margin 34.3%). The net worth stands at ₹2,267.42 Cr (up 16.2% YoY). Total assets are valued at ₹2,560.76 Cr (up 15.9% YoY).

The company has about 505 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

As per MCA filings, the company has open charges of ₹21.87 Cr and satisfied charges of ₹130 Cr on record. Court records list 892 cases involving the company, including 558 filed by the company and 336 filed against it; 204 cases are pending. The company has 14 deals on record (9 market trades, 5 acquisitions); the latest was in October 2022. Its 9 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Strides Pharma Science Limited with revenue of ₹4,624.06 Cr. The company has 24 MSME Form 1 returns on record between 2016 and 2024, listing 1,153 overdue payments to 122 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website india-pharma.gsk.com.

Company details

CIN L24239MH1924PLC001151
Registration Number 001151
Incorporation Date 13 November 1924
ROC Mumbai
Listing Status Listed - Listed on NSE (GLAXO); Listed on BSE (500660)
Company Status Active
Date of Last AGM 27 June 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Glaxosmithkline Pharmaceuticals has undergone 3 name changes throughout its history. The company was previously known as British Drug Houses (India) Private Limited, British Drug Houses (India) Limited, and Glaxo India Limited. The current legal name is Glaxosmithkline Pharmaceuticals Limited.

Company NameStatus
Glaxosmithkline Pharmaceuticals LimitedCurrent
British Drug Houses (India) Private LimitedPrevious
British Drug Houses (India) LimitedPrevious
Glaxo India LimitedPrevious

CIN history

Glaxosmithkline Pharmaceuticals has one previous CIN (Corporate Identification Number): U24239MH1924PTC001151. The current CIN is L24239MH1924PLC001151, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24239MH1924PLC001151Current
U24239MH1924PTC001151Previous
Key People
Bhushan Arun Akshikar Managing Director Ronojit Biswas Whole-Time Director Subesh Ronald Williams Director

Recognitions & Rankings of Glaxosmithkline Pharmaceuticals

Fortune MNC 500 India 2026 edition
Rank#183
Total income
₹3,854 Cr
Profit
₹928 Cr
Last year #181
Stock market indices
Nifty 500 BSE 500

Contact details

Glaxosmithkline Pharmaceuticals Limited's registered office is in Mumbai, Maharashtra. Its website is india-pharma.gsk.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    india-pharma.gsk.com
  • Social Media
  • Registered Address
    Gsk House Dr Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Glaxosmithkline Pharmaceuticals Limited, buy the company report.

Comprehensive company report
Glaxosmithkline Pharmaceuticals Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Business activity

The main business activity of Glaxosmithkline Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Glaxosmithkline Pharmaceuticals Limited, buy the company report.

Financials of Glaxosmithkline Pharmaceuticals Limited

FY 2025-26 filings available

Glaxosmithkline Pharmaceuticals Limited reported revenue of ₹3,821.67 Cr (up 1.9% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹3,822 Cr
+1.9% YoY
EBITDA
₹1,309 Cr
+11.2% YoY
Profit After Tax
₹962 Cr
+10.1% YoY
Net Worth
₹2,267 Cr
+16.2% YoY
Total Assets
₹2,561 Cr
+15.9% YoY
Total Debt
₹33.27 Cr
+234.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,8223,7493,4543,2523,2782,9263,224
Revenue growth+1.9%+8.6%+6.2%-0.8%+12.1%-9.3%-
EBITDA1,3091,177745793740389(231)
EBITDA margin+34.3%+31.4%+21.6%+24.4%+22.6%+13.3%-7.2%
Profit before tax1,4061,2608168392,093525306
Net profit9628746575901,684476144
Net profit margin+25.2%+23.3%+19.0%+18.1%+51.4%+16.3%+4.5%
EPS (₹)61.1554.7634.8336.05100.0421.145.50
Balance sheet
Total assets2,5612,2102,0442,0122,9471,7742,111
Net worth2,2671,9511,7781,7412,6631,4781,821
Total debt33.279.9518.6715.5420.0834.630.18
Cash & bank1,3911,4041,0631,1562,4851,1581,083
Net working capital4523944726621,656862751
Cash flow
Cash from operations9031,290582484811578490
Cash from investing397(45.80)8.71808(406)418(56.84)
Cash from financing(737)(769)(562)(1,543)(524)(696)(428)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9389951,0419808059749491,011
Revenue growth (YoY)+16.6%+2.2%+9.7%-3.1%-1.2%---
Other income43.7635.9550.1036.2143.7240.6835.0739.23
EBITDA296351371336251333292322
EBITDA margin+31.5%+35.3%+35.7%+34.3%+31.2%+34.2%+30.7%+31.8%
Depreciation15.8413.1720.3217.4315.5214.7218.8016.86
Interest0.970.611.190.510.420.580.090.27
Profit before tax322373400354279359308344
Tax85.2795.2410496.5173.9795.7078.2291.31
Net profit237278296257205263230252
EPS (₹)14.0016.4017.4515.0212.1015.5213.5714.91
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,7903,7233,4073,2163,2182,9203,225
Revenue growth+1.8%+9.3%+5.9%-0.0%+10.2%-9.4%-
EBITDA1,3001,169737788734389(213)
EBITDA margin+34.3%+31.4%+21.6%+24.5%+22.8%+13.3%-6.6%
Profit before tax1,3761,2488098352,087524322
Net profit9088276515871,679475197
Net profit margin+24.0%+22.2%+19.1%+18.2%+52.2%+16.3%+6.1%
EPS (₹)59.7354.2534.5135.8899.7921.116.50
Balance sheet
Total assets2,5342,2082,0492,0232,9611,7922,130
Net worth2,2411,9491,7841,7532,6781,4971,840
Total debt33.279.9518.6715.5420.0834.630.18
Cash & bank1,3551,4011,0611,1512,4791,1581,066
Net working capital4113724546441,643866755
Cash flow
Cash from operations8811,280579488820595491
Cash from investing385(36.53)14.97805(420)408(63.10)
Cash from financing(737)(769)(562)(1,544)(524)(696)(428)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9249891,0239748059669461,000
Revenue growth (YoY)+14.9%+2.4%+8.1%-2.6%-0.8%---
Other income61.6335.7131.8233.9143.7639.4635.0636.88
Total expenses631642655639554635656681
EBITDA293347368335251331290319
EBITDA margin+31.7%+35.1%+35.9%+34.4%+31.2%+34.2%+30.7%+31.9%
Depreciation15.8413.1720.3217.4315.5214.7218.8016.86
Interest0.970.611.190.510.420.580.090.27
Profit before tax338369378351279355306339
Tax84.6594.1810195.6573.8794.7677.7790.01

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 29 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9389951,0419808059749491,011
Revenue growth (YoY)+16.6%+2.2%+9.7%-3.1%-1.2%---
Other income43.7635.9550.1036.2143.7240.6835.0739.23
EBITDA296351371336251333292322
EBITDA margin+31.5%+35.3%+35.7%+34.3%+31.2%+34.2%+30.7%+31.8%
Depreciation15.8413.1720.3217.4315.5214.7218.8016.86
Interest0.970.611.190.510.420.580.090.27
Profit before tax322373400354279359308344
Tax85.2795.2410496.5173.9795.7078.2291.31
Net profit237278296257205263230252
EPS (₹)14.0016.4017.4515.0212.1015.5213.5714.91
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,8223,7493,4543,2523,2782,9263,224
Revenue growth+1.9%+8.6%+6.2%-0.8%+12.1%-9.3%-
Other income1661511421141,423218626
Total expenses2,5122,5722,7082,4592,5382,5373,455
Employee cost607580624595610616629
EBITDA1,3091,177745793740389(231)
EBITDA margin+34.3%+31.4%+21.6%+24.4%+22.6%+13.3%-7.2%
Depreciation66.4466.7969.6865.7768.1978.6082.68
Interest2.731.311.801.812.003.536.34
Profit before tax1,4061,2608168392,093525306
Tax370332226229398167213
Net profit9628746575901,684476144
Net profit margin+25.2%+23.3%+19.0%+18.1%+51.4%+16.3%+4.5%
EPS (₹)61.1554.7634.8336.05100.0421.145.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital169169169169169169169
Reserves & surplus2,0981,7821,6081,5722,4941,3091,651
Shareholders' funds (net worth)2,2671,9511,7781,7412,6631,4781,821
Minority interest0.000.000.000.000.000.000.00
Secured loans0.000.000.000.000.000.000.00
Unsecured loans33.279.9518.6715.5420.0834.630.18
Total debt33.279.9518.6715.5420.0834.630.18
Total liabilities2,5612,2102,0442,0122,9471,7742,111
Assets
Gross block7006696666365946031,472
Net block281284321330331387758
Capital work in progress32.9314.3213.9320.3130.5013.21120
Investments1,3921,1188135183660.000.00
Inventories458482525460535547483
Sundry debtors27329322219220521699.80
Cash & bank balances1,3911,4041,0631,1562,4851,1581,083
Loans & advances93.55114175168118282109
Total current assets2,2152,2921,9851,9763,3422,2031,775
Total current liabilities1,7631,8981,5131,3141,6861,3401,024
Net working capital4523944726621,656862751
Total assets2,5612,2102,0442,0122,9471,7742,111
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash53964.1734.9428640510598.78
Net cash from operating activities9031,290582484811578490
Net cash from investing activities397(45.80)8.71808(406)418(56.84)
Net cash from financing activities(737)(769)(562)(1,543)(524)(696)(428)
Net change in cash56347529.23(251)(119)3006.03
Closing cash1,3911,4041,0631,1562,4851,1581,083
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+1.9%+8.6%+6.2%-0.8%+12.1%-9.3%-
EBITDA growth+11.2%+58.0%-6.0%+7.1%+90.4%+268.3%-
PBT growth+11.6%+54.4%-2.8%-59.9%+298.8%+71.7%-55.2%
Net income growth+10.1%+33.1%+11.4%-65.0%+253.7%+231.1%-
Revenue CAGR (3Y)+5.5%+4.6%+5.7%+0.3%+1.6%+0.6%+3.5%
EBITDA CAGR (3Y)+18.2%+16.7%+24.2%-+8.4%-8.4%-
Profitability & leverage
Net income margin+27.1%+24.7%+17.1%+18.8%+51.7%+12.2%+2.9%
Return on capital employed+59.1%+59.3%+45.0%+33.9%+32.6%+32.4%+28.5%
Return on net worth+49.1%+49.8%+37.3%+27.7%+81.3%+28.9%+7.3%
Debt / equity0.010.010.010.010.010.010.00
Long-term debt / equity0.000.000.000.000.010.010.00
Interest cover0.220.120.270.250.301.14-2.02
Efficiency & per share
Fixed asset turnover5.585.625.315.295.482.823.17
Inventory turnover8.147.457.016.546.065.686.65
Debtors turnover13.5114.5716.6716.3615.5818.5529.27
EPS (₹)61.1554.7634.8336.05100.0421.145.50
Dividend per share (₹)57.0054.0032.0032.0090.0030.0040.00
Book value per share (₹)133.85115.19104.93102.79157.1987.26107.47
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9249891,0239748059669461,000
Revenue growth (YoY)+14.9%+2.4%+8.1%-2.6%-0.8%---
Other income61.6335.7131.8233.9143.7639.4635.0636.88
Total expenses631642655639554635656681
EBITDA293347368335251331290319
EBITDA margin+31.7%+35.1%+35.9%+34.4%+31.2%+34.2%+30.7%+31.9%
Depreciation15.8413.1720.3217.4315.5214.7218.8016.86
Interest0.970.611.190.510.420.580.090.27
Profit before tax338369378351279355306339
Tax84.6594.1810195.6573.8794.7677.7790.01
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,7903,7233,4073,2163,2182,9203,225
Revenue growth+1.8%+9.3%+5.9%-0.0%+10.2%-9.4%-
Other income1451471431151,423218624
Total expenses2,4902,5542,6702,4282,4832,5323,438
Employee cost607580624595610616629
EBITDA1,3001,169737788734389(213)
EBITDA margin+34.3%+31.4%+21.6%+24.5%+22.8%+13.3%-6.6%
Depreciation66.4466.7969.6865.7768.1978.6082.68
Interest2.731.311.801.811.993.536.34
Profit before tax1,3761,2488098352,087524322
Tax364329224228397167212
Net profit9088276515871,679475197
Net profit margin+24.0%+22.2%+19.1%+18.2%+52.2%+16.3%+6.1%
EPS (₹)59.7354.2534.5135.8899.7921.116.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital169169169169169169169
Reserves & surplus2,0721,7801,6151,5842,5081,3281,671
Shareholders' funds (net worth)2,2411,9491,7841,7532,6781,4971,840
Secured loans0.000.000.000.000.000.000.00
Unsecured loans33.279.9518.6715.5420.0834.630.18
Total debt33.279.9518.6715.5420.0834.630.18
Total liabilities2,5342,2082,0492,0232,9611,7922,130
Assets
Gross block7006696836365946031,455
Net block281284321330331387758
Capital work in progress32.9314.3213.9320.3130.5013.21120
Investments1,4161,14383854339024.4924.49
Inventories430463514438513523483
Sundry debtors27329322219220521699.80
Cash & bank balances1,3551,4011,0611,1512,4791,1581,066
Loans & advances93.90109155168108275108
Total current assets2,1522,2651,9531,9483,3052,1711,757
Total current liabilities1,7411,8931,4991,3051,6621,3051,002
Net working capital4113724546441,643866755
Total assets2,5342,2082,0492,0232,9611,7922,130
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash53662.1529.7428140598.0397.78
Net cash from operating activities8811,280579488820595491
Net cash from investing activities385(36.53)14.97805(420)408(63.10)
Net cash from financing activities(737)(769)(562)(1,544)(524)(696)(428)
Net change in cash53047432.41(251)(124)3070.25
Closing cash1,3551,4011,0611,1512,4791,1581,066
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+1.8%+9.3%+5.9%-0.0%+10.2%-9.4%-
EBITDA growth+11.2%+58.6%-6.4%+7.3%+89.0%+282.5%-
PBT growth+10.2%+54.3%-3.2%-60.0%+298.3%+62.5%-51.4%
Net income growth+9.8%+27.0%+11.0%-65.1%+253.3%+141.1%-
Revenue CAGR (3Y)+5.6%+5.0%+5.3%-0.1%+0.9%+0.6%+3.6%
EBITDA CAGR (3Y)+18.2%+16.8%+23.8%-+9.2%-8.6%-
Profitability & leverage
Net income margin+26.7%+24.7%+17.2%+18.9%+52.5%+12.2%+3.4%
Return on capital employed+58.2%+58.7%+44.4%+33.6%+32.1%+32.1%+28.4%
Return on net worth+48.3%+49.2%+36.8%+27.4%+80.5%+28.5%+9.9%
Debt / equity0.010.010.010.010.010.010.00
Long-term debt / equity0.000.000.000.000.010.010.00
Interest cover0.220.120.270.250.301.14-2.15
Efficiency & per share
Fixed asset turnover5.545.515.175.235.382.843.20
Inventory turnover8.487.627.166.776.215.806.65
Debtors turnover13.4014.4716.4416.1815.2918.5229.28
EPS (₹)59.7354.2534.5135.8899.7921.116.50
Dividend per share (₹)57.0054.0032.0032.0090.0030.0040.00
Book value per share (₹)132.30115.06105.31103.48158.0688.37108.62

To see the full year-wise statements and ratios of Glaxosmithkline Pharmaceuticals Limited, buy the company report.

Board of directors of Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals has 8 current directors and 31 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Subesh Ronald WilliamsDirector07 Apr 20179 Years 6 MonthsCurrent
Renu Sud Karnad
Also directs: Eih Limited, HDFC Bank Limited, HDFC Asset Management Company Limited and 5 more
Director01 Apr 20197 Years 6 MonthsCurrent
Sunita Maheshwari
Also directs: HDFC Bank Limited, TRS Solutions LLP, Rxdx-Samanvay LLP and 5 more
Director18 May 20206 Years 5 MonthsCurrent
Manu Anand
Also directs: United Breweries Limited
Director16 May 20224 Years 5 MonthsCurrent
Bhushan Arun Akshikar
Also directs: Biddle Sawyer Limited, Organisation of Pharmaceutical Producers of India
Managing Director01 Dec 20223 Years 10 MonthsCurrent
Somasundaram Palamadairamaswamy
Also directs: DCB Bank Limited, India International Bullion Exchange Ifsc Limited
Director26 Mar 20251 Years 7 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Peer comparison

Glaxosmithkline Pharmaceuticals Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Strides Pharma Science Limited₹4,624.06 Cr (FY 2025)18.0%Thane, Maharashtra, India
Apl Healthcare Limited₹4,412.92 Cr (FY 2025)39.0%Hyderabad, Telangana, India
Akums Drugs and Pharmaceuticals Limited₹4,170.28 Cr (FY 2025)-1.0%Delhi, India
J B Chemicals and Pharmaceuticals Limited₹3,956.31 Cr (FY 2025)12.0%Ahmedabad, Gujarat, India
Cadila Pharmaceuticals Limited₹3,869.17 Cr (FY 2025)4.0%Ahmedabad, Gujarat, India
Glaxosmithkline Pharmaceuticals Limitedthis company₹3,821.67 Cr (FY 2026)₹962.15 Cr25.2%1.9%505Mumbai, Maharashtra, India
Acg Associated Capsules Private Limited₹3,600.7 Cr (FY 2025)10.0%Mumbai, Maharashtra, India
Shreya Life Sciences Private Limited₹2,946.23 Cr (FY 2025)284.0%Mumbai, Maharashtra, India
Amneal Pharmaceuticals Private Limited₹2,944.87 Cr (FY 2025)6.0%Ahmedabad, Gujarat, India
Eris Lifesciences Limited₹2,912 Cr (FY 2025)43.0%Ahmedabad, Gujarat, India

To see the full peer comparison of Glaxosmithkline Pharmaceuticals Limited, buy the company report.

Auditor

Glaxosmithkline Pharmaceuticals Limited is audited by DELOITTE HASKINS & SELLS LLP for the financial year 2024.

Auditor firmFinancial yearFirm registration number
DELOITTE HASKINS & SELLS LLPFY 2024117366W/W-100018

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 75.00%, foreign institutional investors hold 4.80%, domestic institutional investors hold 7.80% and retail and other public shareholders hold 12.40%.

Promoters: 75.00%DII (Domestic Institutional): 7.80%FII (Foreign Institutional): 4.80%Retail & Others: 12.40%
Sep 2026
QUARTER
75.00% Promoters
7.80% DII (Domestic Institutional)
4.80% FII (Foreign Institutional)
12.40% Retail & Others
Promoter holding - history
Now 75.00% · Sep 2026High 75.00% · Dec 2025Low 75.00% · Dec 2025
74%74.5%75%75.5%76%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 75.00%Mar 2026: 75.00%Jun 2026: 75.00%Sep 2026: 75.00%75.00%75.00%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters75.00%75.00%75.00%75.00%
Public25.00%25.00%25.00%25.00%

Charges & borrowings

Open charges
₹21.87 Cr
Satisfied charges
₹130 Cr
Breakdown by lending institutions
The Hongkong and Shanghai Banking Corporation Ltd.₹21.87 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
13 Jul 198990231657The Hongkong and Shanghai Banking Corporation Ltd.₹21.87 CrOpen
20 Sep 200490227070Uti Bank Ltd.₹130 CrSatisfied

To see the full charge records of Glaxosmithkline Pharmaceuticals Limited, buy the company report.

Total charge records: 2 View all charges

Deals & funding

Glaxosmithkline Pharmaceuticals Limited has 14 deals on record (9 market trades, 5 acquisitions); the latest was in October 2022.

Total deals
14
Market trades
9
Acquisitions
5

Deals on record (5 of 14)

WhenDealAmountParties
Oct 2022Market trade₹25.49 CrBuyer: Ishares Msci India Small-Cap Etf, an individual
Seller: Ishares Core Emerging Markets Mauritius Co, Ishares India Sc Mauritius Company
Oct 2018AcquisitionUndisclosedBuyer: Eris Oaknet Healthcare Private Limited
Seller: Glaxosmithkline Pharmaceuticals Limited
Dec 2017AcquisitionUndisclosedBuyer: Corona Remedies Limited
Seller: Glaxosmithkline Pharmaceuticals Limited
Apr 2006Acquisition₹207 CrBuyer: an individual
Seller: Glaxosmithkline Pharmaceuticals Limited
Nov 2002Acquisition₹14 CrBuyer: Glenmark Pharmaceuticals Limited
Seller: Glaxosmithkline Pharmaceuticals Limited

To see the full deal history of Glaxosmithkline Pharmaceuticals Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Glaxosmithkline Pharmaceuticals Limited has 24 MSME Form 1 returns on record between 2016 and 2024, listing 1,153 overdue payments to 122 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 122)

SupplierAmount dueDue sinceReported on
Nirtech Private Limited
Everest Industrial Corporation
GVP Forwarder Private Limited
Gig Hospitality Private Limited
an individual supplier

To see the full MSME payment records of Glaxosmithkline Pharmaceuticals Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Glaxosmithkline Pharmaceuticals has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Biddle Sawyer LimitedU51900MH1948PLC006218

To see the full group structure of Glaxosmithkline Pharmaceuticals Limited, buy the company report.

Employees & EPFO

Glaxosmithkline Pharmaceuticals Limited has a workforce of 505 employees on its EPFO records as of Dec 09, 2024, across 4 active EPFO establishments.

Employee count
505
Active EPFO establishments
4
Employee growth
-85.4%

GST

Glaxosmithkline Pharmaceuticals has 28 GST registrations: 24 active and 4 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
28
Active
24
Cancelled / inactive
4
GSTINStateStatusRegistered on
27AAACG4414B1Z8MaharashtraActive01 Jul 2017
27AAACG4414B2Z7MaharashtraActive17 Jul 2017
02AAACG4414B1ZKHimachal PradeshActive01 Jul 2017
03AAACG4414B1ZIPunjabActive01 Jul 2017

To see the full GST registrations and return filing status of Glaxosmithkline Pharmaceuticals Limited, buy the company report.

Recent activity

Glaxosmithkline Pharmaceuticals Limited has 67 board changes on record since 1994: 38 appointments and 29 cessations. The latest: Ronojit Biswas was appointed as Whole-Time Director on 01 Apr 2026.

Appointed
Ronojit Biswas was appointed as Whole-Time Director.
Filing
Glaxosmithkline Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
AGM
Glaxosmithkline Pharmaceuticals Limited last Annual general meeting of members was held on 27 Jun 2025 as per latest MCA records.
Ceased
Anami Narayan Prema Roy ceased to be Director.
Ceased
Sundaram Damodarannair ceased to be Director.
Appointed
Anup Wadhawan was appointed as Director.
Appointed
Somasundaram Palamadairamaswamy was appointed as Director.
Ceased
Pradeep Vasudeo Bhide ceased to be Director.
Appointed
Bhushan Arun Akshikar was appointed as Managing Director.
Ceased
Sridhar Venkatesh ceased to be Managing Director.
Ceased
Nihal Kaviratne ceased to be Director.
Ceased
Mark Robert Dawson ceased to be Director.

61 earlier events are in the company report.

News

Frequently asked questions

Glaxosmithkline Pharmaceuticals is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 13 November 1924 (102+ years old) and is registered under CIN L24239MH1924PLC001151. Listed on BSE: 500660 and NSE: GLAXO.

Glaxosmithkline Pharmaceuticals reported revenue of ₹3,821.67 Cr for FY 2025-26 (up 1.9% YoY) based on consolidated financials.

Glaxosmithkline Pharmaceuticals has 8 current directors:

The latest financial statements of Glaxosmithkline Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 27 June 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Glaxosmithkline Pharmaceuticals is 27AAACG4414B1Z8, registered in Maharashtra. The company has 28 GST registrations in all, of which 24 are active and 4 are cancelled or inactive. Other active GSTINs include 27AAACG4414B2Z7 (Maharashtra), 02AAACG4414B1ZK (Himachal Pradesh), 03AAACG4414B1ZI (Punjab).

The CIN (Corporate Identification Number) of Glaxosmithkline Pharmaceuticals is L24239MH1924PLC001151. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Glaxosmithkline Pharmaceuticals is a listed company as per MCA records. Its shares are listed on both BSE (code: 500660) and NSE (symbol: GLAXO).

Glaxosmithkline Pharmaceuticals has 892 court cases on record: 558 filed by the company and 336 filed against it. 204 are pending. Most are in the high courts.

Glaxosmithkline Pharmaceuticals was incorporated on 13 November 1924, making it 102+ years old. It is registered with the Registrar of Companies, Mumbai.

Glaxosmithkline Pharmaceuticals has 14 deals on record (9 market trades, 5 acquisitions); the latest was in October 2022.

The peers of Glaxosmithkline Pharmaceuticals by revenue are Strides Pharma Science Limited, Apl Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, J B Chemicals and Pharmaceuticals Limited, Cadila Pharmaceuticals Limited and 4 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Ronojit Biswas was appointed as Whole-Time Director on 01 Apr 2026. Anami Narayan Prema Roy ceased to be Director on 29 Mar 2025. Sundaram Damodarannair ceased to be Director on 29 Mar 2025. Glaxosmithkline Pharmaceuticals has 67 board changes on record in total.